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We noted a cluster of 4 cases of infection or coloniza-
tion by Emericella spp., identifi ed by sequence-based anal-
ysis as E. quadrilineata. Sequence-based analysis of an in-
ternational collection of 33 Emericella isolates identifi ed 12 
as E. nidulans, all 12 of which had previously been identi-
fi ed by morphologic methods as E. nidulans. For 12 isolates 
classifi ed as E. quadrilineata, only 6 had been previously 
identifi ed accordingly. E. nidulans was less susceptible than 
E. quadrilineata to amphotericin B (median MICs 2.5 and 
0.5 mg/L, respectively, p<0.05); E. quadrilineata was less 
susceptible than E. nidulans to caspofungin (median MICs, 
1.83 and 0.32 mg/L, respectively, p<0.05). These data in-
dicate that sequence-based identifi cation is more accurate 
than morphologic examination for identifying Emericella 
spp. and that correct species demarcation and in vitro sus-
ceptibility testing may affect patient management.
The genus Aspergillus includes >250 species; ≈20 have been reported to cause opportunistic infections in hu-
mans. The most important human pathogens in this genus 
are A. fumigatus, A. fl avus, A. niger, A. terreus, and Emeri-
cella nidulans (anamorph: A. nidulans) (1). A. fumigatus is 
the most common cause of invasive aspergillosis, a condition 
associated with substantial severity and mortality rates (2). 
Invasive infections caused by E. nidulans are uncommon in 
animals and humans (3–5); in humans they appear to occur 
predominantly in patients who have chronic granulomatous 
disease (CGD), a rare disorder of phagocytes in which the 
absence of both superoxide and hydrogen peroxide produc-
tion in phagocytes predisposes patients to bacterial and fun-
gal infections. Invasive E. nidulans infections in this patient 
group are associated with higher mortality rates than those 
caused by A. fumigatus (6,7). The most common site of in-
fection is the lungs; other manifestations are subcutaneous 
abscesses or liver abscesses, suppurative adenitis, osteomy-
elitis, fungemia, cellulitis, and meningitis (7,8). Within the 
genus Emericella, other species have only rarely been identi-
fi ed as agents of human or animal infections.
The identifi cation of E. nidulans in clinical microbiol-
ogy laboratories is commonly based on the characteristic 
microscopic morphology, the production of hülle cells, or 
the production of ascospores. A. fumigatus is identifi ed by 
its heat tolerance; other species fail to grow when incubated 
at high temperature, typically 48°C.
We recently noted a cluster of infection or colonization 
by E. quadrilineata, a species closely related to E. nidu-
lans. Within a 3-month period, 4 cases were identifi ed at 
the Radboud University Nijmegen Medical Center. No ap-
parent epidemiologic link between the cases was found be-
cause each patient was cared for in a different ward, and 2 
patients with invasive aspergillosis were admitted directly 
from home. One of the latter 2 patients was a 10-year-old 
boy with X-linked CGD and a probable diagnosis of inva-
sive pulmonary aspergillosis (9); the other patient was a 
60-year-old man who had chronic lymphocytic leukemia 
and in whom cerebral aspergillosis later developed and 
was confi rmed by biopsy. From the other 2 patients, who 
had no signs and symptoms of invasive fungal disease, E. 
quadrilineata was cultured from respiratory specimens. No 
laboratory contamination was evident during the period 
in which the cluster occurred. No subsequent cases were 
identifi ed. Morphologic species identifi cation was diffi cult, 
and we had to rely on sequence-based identifi cation, which 
prompted this investigation of the role of E. quadrilineata 
as a causative agent of invasive aspergillosis.
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Methods
Data and Strain Collection
We searched the PubMed literature for cases of infec-
tions caused by E. quadrilineata (anamorph: Aspergillus 
tetrazonus) or E. nidulans; search terms were Emericella, 
quadrilineata, tetrazonus, nidulans, and aspergillosis. For 
those articles that described infections by E. quadrilineata 
or E. nidulans, we asked the authors to send us their iso-
lates for sequence analysis. We also approached colleagues 
who care for patients with CGD or might otherwise have 
a collection of E. nidulans isolates. We also searched our 
department’s fungal culture collection for E. nidulans iso-
lates. It is our policy to store all Aspergillus isolates cultured 
from clinical specimens sent to our laboratory, regardless 
of the clinical relevance of the isolate. Finally, we added 
E. nidulans and E. quadrilineata isolates deposited in the 
culture collection of the Centraal Bureau voor Schimmel-
cultures ([CBS], Utrecht, the Netherlands). The fi nal col-
lection totaled 33 Emericella isolates, with 11 isolates from 
the CBS culture collection (type strains E. quadrilineata, 
E. nidulans, E. nidulans var. echinulata) and 1 isolate from 
the National Collection of Pathogenic Fungi. Ten isolates 
were from our own culture collection (including the 4 en-
countered in the cluster of cases), and 11 isolates were from 
5 other medical centers; some of these isolates had been 
cultured as causes of infection and previously reported 
(online Appendix Table, available from www.cdc.gov/
EID/content/14/4/566-appT.htm) (8,9–12). Seven isolates 
had been cultured from patients with confi rmed invasive 
aspergillosis, and 2 were from patients with probable cases 
(online Appendix Table).
Morphologic Identifi cation
Aspergillus isolates are routinely identifi ed by their 
macroscopic colony morphology and the microscopic mor-
phology of their anamorphic features. When teleomorph 
features were also used to identify an isolate, teleomorph 
nomenclature, such as Emericella spp., was used to report 
the strain. In addition, the isolates were incubated at 48ºC, 
which precludes the growth of most Aspergillus spp. except 
A. fumigatus.
Sequence-based Identifi cation
Sequence-based identifi cation in the routine clinical 
microbiology laboratory was carried out by sequencing of 
parts of the internal transcribed spacer (ITS) 1 and 2 re-
gions. Total DNA of the Emericella cultures was extracted 
by using the MagNa Pure Total NA isolation kit (Roche Di-
agnostics Nederland BV, Almere, the Netherlands). Then 
the ITS 1 and 2 sequence was amplifi ed by PCR with prim-
ers ITS1 (5′-TCCGTAGGTGAACCTGCGG-3′) and ITS4 
(5′-TCCTCCGCTTATTGATATGC-3′) as described (13). 
After purifi cation, the PCR product was sequenced with 
the BigDye Terminator v3 kit (Applied Biosystems, Foster 
City, CA, USA).
In addition to the above-mentioned sequenced-based 
identifi cation, parts of the β-tubulin and calmodulin genes 
were sequenced. The Emericella cultures were cultivated 
in 2 mL malt peptone broth by using 10% (vol/vol) of 
malt extract (Oxoid, Basingstoke, UK) and 0.1% (wt/vol) 
bacto peptone (Difco, Becton Dickinson, Le Pont de Claix, 
France). The cultures were incubated at 25°C for 7 days. 
DNA was extracted from the cells by using the Masterpure 
yeast DNA purifi cation kit (Epicentre Biotechnologies, 
Madison, WI, USA) according to the manufacturer’s in-
structions. Amplifi cation of part of the β-tubulin gene was 
performed by using the primers Bt2a and Bt2b (14,15). 
Amplifi cations of the partial calmodulin gene were set up 
as described (16). Sequence analysis was performed with 
the BigDye Terminator Cycle Sequencing Ready Reac-
tion Kit for both strands. Sequences were aligned by using 
ClustalX software (17) and were improved manually.
Evolutionary distances between the sequences were 
calculated by using the Kimura formula (18) and DNA-
DIST program of the PHYLIP program package (19). Phy-
logenetic trees were prepared by using the neighbor-joining 
method (20) and the NEIGHBOR program of the PHYLIP 
package. Bootstrap values were calculated from 1,000 
replications of the bootstrap procedure by using programs 
SEQBOOT, DNADIST, NEIGHBOR, and CONSENSE 
of the PHYLIP package (19,21). For parsimony analysis, 
PAUP* version 4.0 software was used (22). E. heterothal-
lica was used as an outgroup in these experiments. The 
unique β-tubulin and calmodulin sequences were deposited 
in the GenBank nucleotide sequence database under acces-
sion nos. EF591677–EF591702.
Antifungal-Drug Susceptibility Testing
Antifungal-drug susceptibility testing of Emericella 
isolates was performed by using a microbroth dilution as-
say, as described by the Clinical Laboratory Standards In-
stitute (M38-A) for amphotericin B (Bristol-Myers Squibb, 
Woerden, the Netherlands), itraconazole (Janssen-Cilag, 
Beerse, Belgium), voriconazole (Pfi zer, Capelle aan den 
IJssel, the Netherlands), posaconazole (Schering-Plough, 
Maarsen, the Netherlands), caspofungin (MSD, Haarlem, 
the Netherlands), and terbinafi ne (Novartis, Arnhem, the 
Netherlands) (23). MICs were determined for all drugs ex-
cept caspofungin, for which a microscopic endpoint was 
used (minimum effective concentration) (24). All in vitro 
susceptibility testing was performed in duplicate.
Statistical Analysis
After being transformed logarithmically, MIC dilu-
tions were compared by using the Mann-Whitney U test. 
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Data on growth at different antifungal drug concentrations 
were normalized by setting the corrected optical density of 
the growth control at 0% and the lowest optical density at 
100%. Growth characteristics were analyzed by nonlinear 
regression analysis that used a 4-parameter logistic model 
and created a sigmoidal curve. Test runs determined de-
viation of the model, and goodness-of-fi t was tested by 
determining r2 values. In addition to comparing MICs, we 
determined the drug concentration at which growth was 
50% that of the control (50% maximal effective concentra-
tion [EC50]) and calculated and fi tted the slope of the curve 
(GraphPad Prism, San Diego, CA, USA). For all drugs ex-
cept caspofungin, the EC50 values and slopes were com-
pared for E. nidulans and E. quadrilineata.
Results
Species Identifi cation
The 4 isolates from the cluster of cases grew on Sab-
ouraud-dextrose agar as velvety, brownish-green colonies 
with a purplish reverse side. Conidiophores were light 
brown with hemispherical vesicles bearing metulae and bi-
seriate philalides on the upper half. Conidia were spherical, 
smooth walled, subhyaline, fi nely roughened, and 3–4 μm 
in diameter. After ≈3 weeks of incubation, purple ascocarps 
formed, surrounded by characteristic hülle cells. Asci were 
spherical, 8 spored, 10–13 μm in diameter, and evanescent. 
The ascospores were reddish purple, lenticular, 5–6 × 3–4 
μm, and smooth. The morphologic features were consis-
tent with E. nidulans. As part of the diagnostic process, the 
isolates were incubated at 48ºC, and all isolates showed 
some growth, which was considered inconsistent with E. 
nidulans. Because of this discrepancy, sequence-based 
identifi cation was performed. However, all 33 isolates from 
the subgenus Nidulantes section that were analyzed in this 
study grew at 48°C, which indicates that incubation at this 
temperature does not fully distinguish between this section 
and A. fumigatus.
Sequence-based Analysis
The ITS sequence analysis of the 4 isolates was con-
sistent with that of E. quadrilineata, although there were 
only 1 or 2 mismatches with the base-pair sequence of E. 
nidulans. The morphologic features of E. nidulans and E. 
quadrilineata are very similar; only the microscopic shape 
of the ascospores shows subtle differences. Ascospores 
of E. nidulans have 2 longitudinal crests, as opposed to 
E. quadrilineata, which has 4 short equatorial crests. The 
resolution of the ITS region was considered too low to 
unambiguously differentiate between E. nidulans and E. 
quadrilineata, and further sequence-based identifi cation 
was performed at CBS by using partial β-tubulin and calm-
odulin sequence data.
During analysis of part of partial β-tubulin gene se-
quences, we analyzed 367 bases of all 33 isolates. Among 
the polymorphic sites, 23 were phylogenetically informa-
tive. The neighbor-joining tree (Figure 1) based on partial 
β-tubulin gene sequences had the same topologic features 
as 1 of the 2 maximum-parsimony trees constructed by the 
PAUP program (length 94 steps, consistency index 0.9787, 
retention index 0.9762). The calmodulin dataset included 
489 bases, with 50 parsimony informative sites. The topo-
logic features of the neighbor-joining tree (Figure 2) and 1 
of the 2 most parsimonious trees were the same (tree length 
162, consistency index 0.9691, retention index 0.9854). 
Molecular data indicated that 12 of 33 isolates could be 
classifi ed as E. nidulans, all of which had previously been 
identifi ed as E. nidulans by microscopic examination of 
morphologic characteristics or other methods. For the 12 
isolates classifi ed as E. quadrilineata, only 6 had previous-
ly been identifi ed accordingly. These 6 isolates included 
the 4 in our cluster, 1 from the CBS culture collection, and 
1 previously reported as the cause of onychomycosis (12). 
The remaining 6 isolates had been previously identifi ed as 
E. nidulans (online Appendix Table). Of these, 1 belonged 
to the CBS culture collection, 1 was reported as the cause 
of cerebral aspergillosis (11), and 2 were from patients with 
CGD and confi rmed invasive aspergillosis.
A total of 4 isolates were classifi ed as E. rugulosa, 1 
of which had been previously reported as E. nidulans (10). 
A total of 4 isolates were identifi ed as E. nidulans var. 
echinulata, 2 of which had caused invasive aspergillosis 
in patients with CGD and had been presumptively identi-
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Figure 1. Neighbor-joining tree based on β-tubulin sequence data 
of the Emericella isolates examined. Clinical isolates are set in 
boldface. Numbers above branches are bootstrap values. Only 
values >70% are indicated. T indicates the type strain; * indicates 
the isolates that had been misidentifi ed by morphologic identifi cation 
as E. nidulans. Scale bar represents genetic distance calculated by 
the Kimura 2-parameter model (18).
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fi ed as E. nidulans. Scanning electron microscopy of the 
ascospores of some isolates supported their species assign-
ment (JEOL 5600LV scanning electron microscope [JEOL, 
Tokyo, Japan] equipped with an Oxford CT1500 Cryosta-
tion [Oxford Instruments, Oxford, UK]) (Figure 3) (25).
In Vitro Susceptibility
The in vitro activity of antifungal agents against the 
Emericella isolates is shown in the online Appendix Table. 
Overall, terbinafi ne was the most active drug in vitro, fol-
lowed by posaconazole, which was the most active azole. 
For statistical comparisons, we used 12 E. nidulans and 
12 E. quadrilineata isolates. By comparing MICs, statisti-
cally signifi cant differences in drug activity were found for 
amphotericin B, voriconazole, and posaconazole (Table). 
These differences were also found when EC50 values and 
slopes were compared for both species (data not shown). 
Comparison of minimum effective concentrations showed 
caspofungin to be signifi cantly more active against the E. 
nidulans isolates (p<0.05). Although only 4 E. nidulans 
var. echinulata isolates were analyzed, the susceptibility 
profi le of these isolates was similar to that of E. quadri-
lineata (and not of E. nidulans); for amphotericin B, MICs 
were low, and for caspofungin, MICs were high.
Literature Review
Three cases of infection due to E. quadrilineata have 
been documented. One patient was a 60-year-old man from 
northern India, who had a fi ngernail infection that affected 
all 5 nails of 1 hand. The strain was repeatedly cultured 
from 1 nail, and septate hyphal elements were seen in a 
portion of an excised nail. The patient was treated with 
itraconazole, but the response could not be evaluated (12). 
Invasive aspergillosis caused by E. quadrilineata has been 
described for 2 patients, both of whom had sinusitis. One 
of these, a 28-year-old woman, had acute nonlymphoblas-
tic leukemia and had undergone allogeneic bone marrow 
transplantation. She developed sinusitis with orbital in-
volvement 2 months after transplantation. The diagnosis 
was confi rmed by biopsy, and the patient was successfully 
treated with a combination of surgical debridement, granu-
locyte transfusions, and intravenous amphotericin B–cho-
lesterol sulfate colloidal dispersion (26). The other patient 
was a 28-year-old man who had received an allogeneic bone 
marrow transplant for acute myeloid leukemia. Left orbital 
swelling, facial pain, and nasal congestion developed 68 
days after transplantation. E. quadrilineata was cultured 
from a biopsy specimen; the patient was successfully treat-
ed with external ethmoidectomy, granulocyte transfusions, 
and topical and systemic therapy with a lipid formulation of 
amphotericin B. The fungal infection resolved (27).
Discussion
Until this report, 2 cases of invasive aspergillosis 
caused by E. quadrilineata had been described; each 
case had been reported as sinusitis in patients who had 
undergone bone marrow transplantation for hematologic 
malignancy. We add 1 case of central nervous system 
aspergillosis and 3 cases of invasive pulmonary aspergil-
losis in patients with CGD. The 3 cases may not be sur-
prising because E. quadrilineata is very closely related 
to E. nidulans, a fungus known to cause infections in hu-
mans (3,5,28–30), primarily in patients with CGD (6,7). 
Emericella spp. other than E. nidulans are less frequently 
reported as causative agents of infectious disease. In addi-
tion to the above-mentioned human infections, E. quadri-
lineata has been identifi ed as a causative agent of mycosis 
in animals (31). We have found only 1 report each of E. 
rugulosa (4) and E. nidulans var. echinulata (32) as the 
cause of human or animal infections.
Discriminating E. nidulans and E. quadrilineata by 
morphologic characteristics is virtually impossible. Only 
the ascospore ornamentation differs, and the subtle differ-
ences cannot be seen by using light microscopy. The most 
frequently used technique for their unambiguous identifi ca-
tion is scanning electron microscopic examination of the 
lining of the ascospores (25). However, fruiting bodies are 
usually formed after a rather long incubation period (1–2 
weeks). And although E. nidulans was found to form cle-
istothecia in the human body (33), clinical isolates often 
lose their ability to form sexual reproductive structures and 
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Figure 2. Neighbor-joining tree based on calmodulin sequence 
data of Emericella isolates examined. Clinical isolates are set in 
boldface. Numbers above branches are bootstrap values. Only 
values >70% are indicated. T indicates the type strain; * indicates 
the isolates that had been misidentifi ed by morphologic identifi cation 
as E. nidulans. Scale bar represents genetic distance calculated by 
the Kimura 2-parameter model (18).
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ascospores (34,35). Given these diffi culties, we anticipate 
that reliance on phenotypic characteristics alone would 
cause misidentifi cation of E. nidulans, rather than correct 
identifi cation of E. quadrilineata, as the cause of invasive 
aspergillosis. The sequence-based analysis showed that this 
was indeed the situation; 50% of the E. quadrilineata iso-
lates had previously been identifi ed as E. nidulans. Among 
these was a case of cerebral aspergillosis, the second case 
observed in our cluster of cases. Despite the close mor-
phologic and genetic relatedness between E. nidulans and 
E. quadrilineata, the activity of antifungal agents differed 
signifi cantly, which supports the conclusion that biological 
differences exist between these species. The triazoles were 
active in vitro; posaconazole showed the greatest activity, 
which is also observed for most Aspergillus spp. Although 
signifi cant differences were found for activity of voricon-
azole and posaconazole, these differences appear to be 
not clinically relevant, given the small differences in MIC 
values (Table). However, for amphotericin B and caspo-
fungin, the observed differences in activity may be clini-
cally important. Amphotericin B was less active against E. 
nidulans than against E. quadrilineata. In vitro resistance 
of E. nidulans against amphotericin B has been recognized 
(36), although the testing method has been shown to sub-
stantially affect the activity found (37). However, lack of 
activity of amphotericin B has also been reported in ex-
perimental models of infection and in cases reported in the 
literature (8,38). Caspofungin was less active against E. 
quadrilineata than against E. nidulans. Caspofungin was 
shown to be effective against E. nidulans in a murine mod-
el of systemic infection (38), but no data are available for 
E. quadrilineata. Although the allylamine terbinafi ne is not 
used for treatment of patients with invasive aspergillosis, 
the drug is highly active against both E. nidulans and E. 
quadrilineata. The isolates were inhibited at concentrations 
as low as 0.015 mg/L.
Identifi cation of molds primarily relies on morpho-
logic criteria such as the macroscopic colony morphol-
ogy and the microscopic morphology of the conidia and 
the structures bearing the conidia. Morphologic identifi ca-
tion underestimates differences among species and among 
members of the same species. This was recently shown 
for the section Fumigati, in which A. lentulus and A. uda-
gawae were among isolates phenotypically identifi ed as A. 
fumigatus (34,35). We made a similar observation when 10 
of 33 Emericella isolates were found to be misidentifi ed. 
Correct species demarcation is important from a taxonom-
ic viewpoint but can also have clinical relevance. Within 
the Aspergillus section of Fumigati, the newly identifi ed 
species A. lentulus was shown to be more resistant than 
A. fumigatus to antifungal drugs (35). Therefore, correct 
species identifi cation will affect the choice of antifungal 
therapy. Differences in drug activity were also apparent 
in the Emericella spp. we examined. Another important 
reason for correct species identifi cation is the detection of 
outbreaks of infection, which could warrant interventions 
to prevent invasive fungal infection in immunocompro-
mised persons or lead to epidemiologic surveys to identify 
sources of spread of fungal spores. However, the resolution 
of sequencing of the ITS region is too low to reliably dif-
570 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 4, April 2008
Table. Antifungal activities against Emericella nidulans  and E. quadrilineata
MIC, mean 
Drug E. nidulans (n = 12) E. quadrilineata (n = 12) Significance*
Amphotericin B 2.5 0.5 p<0.05
Itraconazole 0.07 0.13 NS
Voriconazole 0.26 0.39 p<0.05
Posaconazole 0.25 0.22 p<0.05
Caspofungin† 0.32 1.83 p<0.05
Terbinafine 0.01 0.009 NS
*NS, not significant. 
†Mean minimum effective concentration was compared. 
Figure 3. Scanning electron microscopic images of ascospores of some Emericella isolates. A) E. quadrilineata V43-63; B) E. rugulosa 
V43-77; C) E. nidulans var. echinulata 4606. Scale bars represent 5 μm.
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ferentiate between E. nidulans and E. quadrilineata; there-
fore, in vitro susceptibility testing might be appropriate in 
those laboratories that do not have access to sequencing of 
β-tubulin and calmodulin genes.
Molecular techniques in addition to morphologic iden-
tifi cation have identifi ed a role of E. quadrilineata as an 
opportunistic fungal pathogen, especially in patients with 
CGD and in those with hematologic malignancy. These mo-
lecular techniques will help identify and discriminate more 
accurately within the current fungal species and will give 
more insight into the pathogenesis of fungal infection.
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